Link Biologics is on a mission to develop Link_TSG6 as a superior treatment for the life-limiting effects of inflammatory and degenerative disorders. Link_TSG6 is based on TSG-6, a human protein with an endogenous role to protect tissues from inflammatory damage. Our lead programme, Dry Eye Disease (DED), is an inflammatory condition where patients experience persistent eye irritation, blurred vision, pain and decreased quality of life. Approximately 350 million people live with DED worldwide.